A one-year survey of candidemia in Belgium in 2002

Epidemiology and Infection

Volumn 132, Issue 6, 2004, Pages 1175-1180

  Swinne, D ^a   Watelle, M ^a   Suetens, C ^a   Mertens, K ^a   Fonteyne, P A ^a   Nolard, N ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; PYRROLE DERIVATIVE;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BELGIUM; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; FUNGUS ISOLATION; HEALTH SURVEY; HOSPITALIZATION; HUMAN; IN VITRO STUDY; INCIDENCE; INTENSIVE CARE UNIT; INTRAVASCULAR CATHETER; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PICHIA; SACCHAROMYCES CEREVISIAE; SPECIES DIFFERENCE; TRICHOSPORON;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BELGIUM; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; FUNGEMIA; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE;

EID: 10444258018     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S095026880400295X     Document Type: Article

References (26)

1. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-244.
2. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-3259.
3. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-1849.
4. Baran J, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infect Dis 2001; 33: 137-139.
5. Suetens C, Jans B, Versporten A, Leens E, Carsauw H, Morales I. Surveillance of noscomial septicaemia in Belgian hospitals. Results from the national network of surveillance, 1992-2001 [in French], 17th Scientific Institute Public Health Meeting (30 November 2001): Diagnosis and surveillance of infectious diseases: 15-19.
6. Barnett JA, Payne RW, Yarrow D. Yeasts: characteristics and identification, 3rd edn. Cambridge University Press, 2000: 1140 pp.
7. NCCLS, 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Marr KA. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr Opin Infect Dis 2000; 13: 615-620.
9. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001; 7 (Suppl 2): 1-7.
10. Doczi I, Dosa E, Hadju E. Nagy E. Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000. J Med Microbiol 2002; 51: 677-681.
11. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M and the Norwegian Yeast Study Group. Constant low rate of fungemia in Norway, 1991 to 1996. J Clin Microbiol 1998; 36: 3455-3459.
12. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002; 40: 3489-3492.
13. Richet H, Roux P, Des Champs C, Esnault Y, Andremont A and the French Candidemia Study Group. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002; 8: 405-412.
14. Farina C, Vailati F, Manisco A, Goglio A. Fungaemia survey: a 10-year experience in Bergamo, Italy. Mycoses 1998; 42: 543-548.
15. Michel-Nguyen A, Favel A, Azan P, Regli P, Penaud A. Nineteen years epidemiologic data in a university hospital: importance of Candida (Torulopsis) glabrata; susceptibility [in French]. J Mycol Med 2000; 10: 76-86.
16. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ and the SENTRY participants Group. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997-2000. J Clin Microbiol 2002; 40: 852-856.
17. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002: 35: 627-630.
18. Weems JJ. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations and antimicrobial susceptibility. Clin Infect Dis 1992; 14: 756-766.
19. Levin AS, Costa SF, Mussi NS, et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998; 30: 243-149.
20. Matsumoto FE, Gandra RF, Ruiz LS, et al. Yeasts isolated from blood and catheter in children from a Public Hospital of Sao Paulo, Brazil. Mycopathologia 2001; 154: 63-69.
21. Lupetti A, Tavanti A, Davini P, et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 2002; 40: 2363-2369.
22. Safdar A, Perlin D, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002; 44: 11-16.
23. Yoon SA, Vazquez JA, Steffan PE, Sobel JD, Akins RA. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from Amphotericin B susceptibility to resistance. Antimicrob Agents Chemother 1999; 43: 836-845.
24. Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA and the FIMUA-ECMM candidaemia study group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003; 52: 679-682.
25. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-1170.
26. Colombo AL, Nakagawa Z, Valdetaro F, Branchini MLM, Kussano EJU, Nucci M. Susceptibility profile of 200 bloodstream isolates of Candida spp. collected from Brazilian tertiary care hospitals. Med Mycol 2003; 41: 235-239.